Compass Pathways Q3 net loss narrows to $9.8 million on $40.8 million warrant gain
Compass Pathways reported third quarter 2026 results. Net loss narrowed to $9.8 million from $137.7 million a year earlier, mainly because of a non-cash $40.8 million gain on warrant fair value, while operating expenses rose to $56.4 million from $40.5 million as the company prepares a potential launch. The company says its final NDA submission for COMP360 will be filed within two weeks and that cash of $444.0 million is expected to fund operations into 2028.
Key points
- Net loss was $9.8 million, or $0.07 per share basic, versus $137.7 million, or $1.44 per share, a year earlier; the company attributes the decrease mainly to the warrant fair value gain.
- Selling, general and administrative expenses rose to $33.0 million from $13.2 million, reflecting commercial preparedness costs; research and development fell to $23.5 million from $27.3 million.
- Final NDA submission for COMP360 is expected within the next two weeks, with launch targeted for the first half of 2027, subject to FDA approval.
- Cash and cash equivalents were $444.0 million at September 30, 2026, against debt of $51.0 million.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.